Arena BioWorks Wants To Address Inefficiency Of Early R&D Finance

Incubator Will Use Hub-And-Spoke Model

Backed with $500m to look into the mechanistic underpinnings of unmet medical needs, Arena BioWorks will employ a hub-and-spoke model to incubate biotechs around a central technology hub.

Arena
Arena BioWorks will put discovery and company creation under one roof • Source: Shutterstock

Broad Institute co-founder Stuart Schreiber is teaming up with an all-star list of scientists and financial backers to found Arena BioWorks, which Schreiber said is intended to let scientists focus on developing their hypotheses rather than seeking government grants and then later on, if their research yields something of therapeutic potential, venture capital funding.

Key Takeaways
  • Arena BioWorks will seek to fund researcher-driven science into mechanistic understanding of disease that will be allowed to develop over long timeframes.

  • A key...

Based in Cambridge, MA, the institute will support basic scientific research into the mechanisms of human disease and the translation of promising findings into drug candidate research and development, through...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By 

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Bristol Will Pay BioNTech $1.5bn Up Front To Enter PD-L1xVEGF Space

 
• By 

BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By 

Buy boosts the French major's immunology pipeline.

More from Business

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By 

Buy boosts the French major's immunology pipeline.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: a preview of major ASCO readouts; Roivant stays patient in deals; Lilly diversifies pain pipeline with SiteOne acquisition; Nucala gets US COPD nod; and women in Indian pharma.